Thomas Powles, MBBS, MRCP, MD shares the groundbreaking results of the NIAGARA study, a global phase 3 trial involving 1,000 patients with muscle-invasive bladder cancer. Dr. Powles breaks down the trial’s design, including the addition of perioperative durvalumab to the standard chemotherapy and cystectomy regimen. The study revealed significant improvements in both event-free survival and overall survival, marking the first time immune therapy has shown a survival advantage in this patient population.
Advertisement
Latest News
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
UGN-102 could become the first FDA-approved therapy for low-grade intermediate-risk non-muscle invasive bladder cancer.
In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024.
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.
In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.
In part 1, the panelists examine the evolving treatment landscape of MIBC and NMIBC, including discussion on new trials.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhDEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
The Uromigos Live and Unplugged 2024
The Uromigos Live & Unplugged 2024 will take place September 27-29 in Nashville, Tennessee.
This meeting is the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
Expert Interviews
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and leading in urology.
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Dr. Choueiri outlines the importance of experts putting their heads together to decide on how to approach gray areas.
The panelists wrap up this peri-operative therapy session with what the envision for the future for sparing bladders.
Video Insights
Clinical discussions with experts in the field
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.